GlassScriptPhysician profile
James R Mccarty
NPI 1104871904
$19,016.78
in general payments reported to CMS, 2019-2025
35 companies · $3,484 in 2025
The $3,484 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,213 · 2020: $1,569 · 2021: $1,532 · 2022: $2,451 · 2023: $3,591 · 2024: $3,178 · 2025: $3,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,699 · Consulting Fee: $430 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,699.19 |
| Consulting Fee | $430.00 |
| Education | $123.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,438.20 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,057.61 | 2019-2025 | |
| Lilly USA, LLC | $1,405.04 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $1,260.09 | 2019-2025 | |
| Incyte Corporation | $1,020.25 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $979.61 | 2020-2025 | Ilumya, Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $865.19 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Mayne Pharma Commercial LLC | $861.10 | 2019-2025 | |
| Ucb, INC. | $834.99 | 2019-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $744.48 | 2023-2025 | Zoryve |
| Pfizer INC. | $704.59 | 2019-2025 | |
| Leo Pharma INC. | $682.64 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $605.67 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $533.97 | 2022-2025 | Sotyktu, Sprycel |
| Regeneron Pharmaceuticals, INC. | $526.08 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $494.76 | 2019-2025 | Tremfya, Simponi, Stelara |
| Dermavant Sciences, INC. | $486.35 | 2023-2024 | Vtama |
| Almirall LLC | $258.36 | 2021-2025 | Klisyri, Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $229.23 | 2019-2023 | Targretin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.33 | 2023-2024 | Spevigo, Cyltezo |
| Amgen INC. | $180.67 | 2019-2025 | Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $146.31 | 2025 | Tremfya |
| Prugen, INC. Pharmaceuticals | $140.00 | 2021 | |
| Allergan, INC. | $105.17 | 2019-2021 | |
| Journey Medical Corporation | $59.25 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $55.94 | 2020-2021 | |
| Kyowa Kirin, INC. | $39.35 | 2024 | Poteligeo |
| Genentech USA, INC. | $17.63 | 2019 | |
| Bard Peripheral Vascular, INC. | $17.57 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $17.23 | 2023 | Neo-Synalar |
| Biofrontera INC. | $15.87 | 2020 | |
| Sebela Pharmaceuticals INC. | $14.87 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $14.41 | 2019 | |
| Dusa Pharmaceuticals, INC. | $13.51 | 2019 | |
| Organon LLC | $5.46 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mccarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.